Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Preferred Stock Liabilities (2018 - 2019)

Bicycle Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $27.3 million for Q1 2019.

  • For Q1 2019, Preferred Stock Liabilities fell 34.63% year-over-year to $27.3 million; the TTM value through Mar 2019 reached $27.3 million, down 34.63%, while the annual FY2018 figure was $41.8 million, 23.44% down from the prior year.
  • Preferred Stock Liabilities reached $27.3 million in Q1 2019 per BCYC's latest filing, down from $41.8 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $54.6 million in Q2 2018 to a low of $27.3 million in Q1 2019.